Familial rhabdoid tumour 'avant la lettre' - From pathology review to exome sequencing and back again

Journal of Pathology

Volumn 231, Issue 1, 2013, Pages 35-43

  Witkowski, Leora ^a,b   Lalonde, Emilie ^a   Zhang, Jian ^a   Albrecht, Steffen ^c   Hamel, Nancy ^a,d   Cavallone, Luca ^a,b   May, Sandra Thompson ^e   Nicholson, James C ^f   Coleman, Nicholas ^g   Murray, Matthew J ^f,g   Tauber, Peter F ^h   Huntsman, David G ^i,j   Schönberger, Stefan ^k   Yandell, David ^e   Hasselblatt, Martin ^l   Tischkowitz, Marc D ^g   Majewski, Jacek ^a   Foulkes, William D ^a,b,d  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MONTREAL CHILDREN S HOSPITAL   (Canada)

^d MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^e UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^f CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^g UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^h St Mary's Hospital Siegen   (Germany)

ⁱ BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^j VANCOUVER GENERAL HOSPITAL   (Canada)

^k UNIVERSITY OF BONN   (Germany)

^l UNIVERSITY HOSPITAL MÜNSTER   (Germany)

more..

Author keywords

Cancer; Chromatin remodelling; Exome sequencing; Germ cell tumour; Ovarian; Rhabdoid tumour; SMARCA4

Indexed keywords

DISEASE PREDISPOSITION; DNA EXTRACTION; EXOME; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GERM CELL TUMOR; HUMAN; IMMUNOHISTOCHEMISTRY; MICROSCOPY; NONSENSE MUTATION; PATHOLOGY; PRIORITY JOURNAL; REVIEW; RHABDOID TUMOR;

EID: 84885134944     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4225     Document Type: Review

References (42)

1. Eaton KW, Tooke LS, Wainwright LM, et al. Spectrum of SMARCB1/INI1 mutations in familial and sporadic rhabdoid tumors. Pediatr Blood Cancer 2011; 56: 7-15
2. Schneppenheim R, Fruhwald MC, Gesk S, et al. Germline nonsense mutation and somatic inactivation of SMARCA4/BRG1 in a family with rhabdoid tumor predisposition syndrome. Am J Hum Genet 2010; 86: 279-284.
3. Hasselblatt M, Gesk S, Oyen F, et al. Nonsense mutation and inactivation of SMARCA4 (BRG1) in an atypical teratoid/rhabdoid tumor showing retained SMARCB1 (INI1 ) expression. Am J Surg Pathol 2011; 35: 933-935.
4. Poremba C, Dockhorn-Dworniczak B, Merritt V, et al. Immature teratomas of different origin carried by a pregnant mother and her fetus. Diagn Mol Pathol 1993; 2: 131-136.
5. World Health Organization. Pathology and genetics of tumours of the breast and female genital organs. In World Health Organization Classification of Tumours, 3rd edn, Tavassoli FA, Devilee P (eds). IARC Press: Lyon, 2003.
6. Talerman A, Vang R. Germ cell tumors of the ovary. In Blaustein's Pathology of the Female Genital Tract, 6th edn, Kurman RJ, Ellenson LH, Ronnett BM (eds). Springer: New York, 2011; 847-907.
7. DePristo MA, Banks E, Poplin R, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet 2011; 43: 491-498.
8. Tohda H, Oikawa A, Kudo T, et al. A greatly simplified method of establishing B-lymphoblastoid cell lines. Cancer Res 1978; 38: 3560-3562.
9. Rio Frio T, Wade NM, Ransijn A, et al. Premature termination codons in PRPF31 cause retinitis pigmentosa via haploinsufficiency due to nonsense-mediated mRNA decay. J Clin Invest 2008; 118: 1519-1531.
10. Judkins AR, Burger PC, Hamilton RL, et al. INI1 protein expression distinguishes atypical teratoid/rhabdoid tumor from choroid plexus carcinoma. J Neuropathol Exp Neurol 2005; 64: 391-397.
11. Forbes SA, Bindal N, Bamford S, et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 2011; 39: D945-950.
12. Lefkowitz IB, Rorke LB, Packer RJ, et al. Atypical teratoid tumor of infancy: definition of an entity. Ann Neurol 1987; 22: 448-449.
13. Roberts C, Biegel J. The role of SMARCB1/INI1 in the development of rhabdoid tumors. Cancer Biol Ther 2009; 8: 412-416.
14. Banzai C, Yahata T, Sasahara J, et al. Advanced malignant rhabdoid tumor of the ovary effectively responding to chemotherapy: a case report and review of the literature. Gynecol Oncol 2007; 105: 261-265.
15. Taylor MD, Gokgoz N, Andrulis IL, et al. Familial posterior fossa brain tumors of infancy secondary to germline mutation of the hSNF5 gene. Am J Hum Genet 2000; 66: 1403-1406.
16. Wu JI. Diverse functions of ATP-dependent chromatin remodeling complexes in development and cancer. Acta Biochim Biophys Sin (Shanghai) 2012; 44: 54-69.
17. Wong AK, Shanahan F, Chen Y, et al. BRG1, a component of the SWI-SNF complex, is mutated in multiple human tumor cell lines. Cancer Res 2000; 60: 6171-6177.
18. Gunduz E, Gunduz M, Ouchida M, et al. Genetic and epigenetic alterations of BRG1 promote oral cancer development. Int J Oncol 2005; 26: 201-210.
19. Sun A, Tawfik O, Gayed B, et al. Aberrant expression of SWI /SNF catalytic subunits BRG1/BRM is associated with tumor development and increased invasiveness in prostate cancers. Prostate 2007; 67: 203-213.
20. Wilson BG, Roberts CW. SWI /SNF nucleosome remodellers and cancer. Nat Rev Cancer 2011; 11: 481-492.
21. Decristofaro MF, Betz BL, Rorie CJ, et al. Characterization of SWI/SNF protein expression in human breast cancer cell lines and other malignancies. J Cell Physiol 2001; 186: 136-145.
22. Grand F, Kulkarni S, Chase A, et al. Frequent deletion of hSNF5/INI1 , a component of the SWI /SNF complex, in chronic myeloid leukemia. Cancer Res 1999; 59: 3870-3874.
23. Shain AH, Giacomini CP, Matsukuma K, et al. Convergent structural alterations define SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeler as a central tumor suppressive complex in pancreatic cancer. Proc Natl Acad Sci USA 2012; 109: E252-259.
24. Wang DD, Chen YB, Pan K, et al. Decreased expression of the ARID1A gene is associated with poor prognosis in primary gastric cancer. PLoS One 2012; 7: e40364-40364.
25. Wang K, Kan J, Yuen ST, et al. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet 2011; 43: 1219-1223.
26. Wiegand KC, Lee AF, Al-Agha OM, et al.. Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas. J Pathol 2011; 224: 328-333.
27. Guan B, Gao M, Wu CH, et al. Functional analysis of in-frame indel ARID1A mutations reveals new regulatory mechanisms of its tumor suppressor functions. Neoplasia 2012; 14: 986-993.
28. Le Gallo M, O'Hara AJ, Rudd ML, et al. Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. Nat Genet 2012; 44: 1310-1315.
29. Mamo A, Cavallone L, Tuzmen S, et al. An integrated genomic approach identifies ARID1A as a candidate tumor-suppressor gene in breast cancer. Oncogene 2012; 31: 2090-2100.
30. Delbove J, Rosson G, Strobeck M, et al. Identification of a core member of the SWI /SNF complex, BAF155/SMARCC1, as a human tumor suppressor gene. Epigenetics 2011; 6: 1444-1453.
31. Jones DT, Jager N, Kool M, et al. Dissecting the genomic complexity underlying medulloblastoma. Nature 2012; 488: 100-105.
32. Hu Q, Rosenfeld MG. Epigenetic regulation of human embryonic stem cells. Frontiers Genet 2012; 3: 238.
33. Lee RS, Stewart C, Carter SL, et al. A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers. J Clin Invest 2012; 122: 2983-2988.
34. Martini M, Vecchione L, Siena S, et al. Targeted therapies: how personal should we go? Nat Rev Clin Oncol 2012; 9: 87-97.
35. Koboldt DC, Fulton RS, McLellan MD, et al. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61-70.
36. Colombo N, Peiretti M, Garbi A, et al. Non-epithelial ovarian cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23: vii20-26.
37. Poremba C, Dockhorn-Dworniczak B, Merritt V, et al. Immature teratomas of different origin carried by a pregnant mother and her fetus. Diagn Mol Pathol 1993; 2: 131-136.
38. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009; 25: 1754-1760.
39. Li H, Handsaker B, Wysoker A, et al. The sequence alignment/ map (SAM) format and SAMtools. Bioinformatics 2009; 25: 2078-2079.
40. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 2010; 38: e164.
41. Zhang J, Shi Y, Lalonde E, et al. Exome profiling of primary, metastatic and recurrent ovarian carcinomas in a BRCA1-positive patient. BMC Cancer 2013; 13: 146.
42. Sikkema-Raddatz B, Johansson LF, de Boer EN, et al. Targeted next-generation sequencing can replace Sanger sequencing in clinical diagnostics. Hum Mutat 2013; 34: 1035-1042.